8.000USD+3.23%Mkt Cap: 33.50M USDP/E: —Last update: 2026-06-01
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap33.50M USD
Enterprise Value50.77M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.28M USD
Revenue/Share—
Last Price8.000 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees18
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.42
EV/Revenue—
P/S—
P/B-1.87
EPS (TTM)-6.44
EPS (Forward)—
52W Range
4.1355% of range75.50
52W High75.50 USD
52W Low4.135 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE319.08%
ROA-599.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.33M USD
CapEx (TTM)64.44K USD
FCF Margin—
FCF Yield-9.46%
Net Debt8.78M USD
Net Debt/EBITDA-0.42
Balance Sheet
Debt/Equity-0.91
Current Ratio0.29
Quick Ratio0.12
Book Value/Sh-4.2370 USD
Cash/Share0.1650 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMar 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.19M
Float1.08M
Insiders74.41%
Institutions3.62%
Short Interest
Short Ratio4.5d
Short % Float7.90%
Short % Out.2.85%
Shares Short119.46K
Short (prev mo.)91.21K
Technical
SMA 506.796 (+17.7%)
SMA 20021.19 (-62.2%)
Beta0.10
S&P 52W Chg27.70%
Avg Vol (30d)31.42K
Avg Vol (10d)43.06K
Technical Indicators
RSI (14)48.5
MACD0.3810
MACD Signal0.5168
MACD Hist.-0.1358
BB Upper10.93 USD
BB Middle8.187 USD
BB Lower5.440 USD
BB Width67.12%
ATR (14)1.447 USD
Vol Ratio (20d)0.68x